Papers

2

Total Citations

60

H-Index

2

About

Monika Janda is a leading behavioral scientist and cancer control researcher whose work bridges clinical trials, patient decision-making, and health services research. Her primary focus lies in improving outcomes for women with gynecological cancers, particularly through understanding patient preferences and optimizing surgical interventions. Her most impactful contribution is the landmark ENDO-3 trial (2021, 47 citations), a phase III randomized clinical study that evaluated sentinel node biopsy versus no retroperitoneal node dissection in early-stage endometrial cancer, providing critical evidence for de-escalating surgical morbidity. Janda also explores the psychosocial dimensions of women’s health, as seen in her work on factors influencing hysterectomy decision-making (2017, 13 citations), which sheds light on how patients weigh risks, benefits, and personal values. Her research has shaped clinical guidelines and empowered patients to make informed choices. With a career spanning behavioral science, oncology, and public health, Janda’s work is widely cited for its practical impact on cancer care delivery and quality of life.

Research Focus

Key Achievements

2
H-Index
2
Papers
60
Total Citations
30
Avg Citations/Paper
🏆 Most Cited Paper
A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020
47 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: The University of Queensland, Queensland University of Technology

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago